Patient Preference Distribution for Use of Statin Therapy

被引:11
作者
Brodney, Suzanne [1 ]
Valentine, K. D. [2 ]
Sepucha, Karen [2 ]
Fowler, Floyd J., Jr. [3 ]
Barry, Michael J. [1 ]
机构
[1] Massachusetts Gen Hosp, Informed Med Decis Program, 100 Cambridge St,16th Floor, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Hlth Decis Sci Ctr, Boston, MA 02114 USA
[3] Univ Massachusetts, Ctr Survey Res, Boston, MA 02125 USA
关键词
CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; GUIDELINES; OUTCOMES; SAFETY;
D O I
10.1001/jamanetworkopen.2021.0661
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Thresholds for initiating statin therapy should be informed by patients' preferences. OBJECTIVE To define the preference distribution for statin therapy across the spectrum of cardiovascular disease (CVD) risk after participants were informed about the benefits and harms of statin therapy. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional survey was conducted from May 13 to June 2, 2020. Participants included 304 individuals aged 40 to 75 years drawn from a nonprobability opt-in panel who had not taken a statin or proprotein convertase subtilisin/kexin type 9 inhibitor in the past 3 years and knew the results of their total cholesterol, high-density lipoprotein cholesterol, and blood pressure measurements. EXPOSURES Personalized 10-year CVD risk with and without statin therapy and potential harms of statins. MAIN OUTCOMES AND MEASURES The primary outcome was self-reported preference for statin therapy. RESULTS The 304 participants had a mean (SD) age of 54.8 (9.9) years; 152 were women (50.0%), 130 (42.8%) non-White, 50 (16.6%) had a high school degree or less education, and 153 (50.8%) reported never needing help reading health materials. When asked their preference for using statin therapy after reviewing their benefit and risk information, 45% of the participants reported they would definitely or probably choose statin therapy. As the risk increased, the proportion who would choose statin therapy generally increased (from 31.1% for a risk 50%). The minimum risk threshold had to increase to 20% before 75% of respondents in that risk group would want statin therapy. For participants with a risk greater than 10%, the desire to use statin therapy decreased as participants' health literacy, subjective numeracy, and knowledge scores increased. CONCLUSIONS AND RELEVANCE In this study, preferences for statin therapy for primary prevention of CVD appeared to vary across the spectrum of 10-year cardiovascular risk, but they were relatively flat at intermediate levels of risk. This preference distribution suggests a broad risk range for shared decision-making.
引用
收藏
页数:10
相关论文
共 20 条
[1]  
[Anonymous], QUICK FACTS
[2]  
Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000677, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.010]
[3]   Reform of the National Screening Mammography Program in France [J].
Barratt, Alexandra ;
Jorgensen, Karsten Juhl ;
Autier, Philippe .
JAMA INTERNAL MEDICINE, 2018, 178 (02) :177-178
[4]   Statin Use for the Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force Recommendation Statement [J].
Bibbins-Domingo, Kirsten ;
Grossman, David C. ;
Curry, Susan J. ;
Davidson, KarinaW. ;
Epling, John W., Jr. ;
Garcia, Francisco A. R. ;
Gillman, Matthew W. ;
Kemper, Alex R. ;
Krist, Alex H. ;
Kurth, Ann E. ;
Landefeld, C. Seth ;
LeFevre, Michael L. ;
Mangione, Carol M. ;
Phillips, William R. ;
Owens, Douglas K. ;
Phipps, Maureen G. ;
Pignone, Michael P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19) :1997-2007
[5]   Statins for Prevention of Cardiovascular Disease in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force [J].
Chou, Roger ;
Dana, Tracy ;
Blazina, Ian ;
Daeges, Monica ;
Jeanne, Thomas L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19) :2008-2024
[6]   Interpretation of the evidence for the efficacy and safety of statin therapy [J].
Collins, Rory ;
Reith, Christina ;
Emberson, Jonathan ;
Armitage, Jane ;
Baigent, Colin ;
Blackwell, Lisa ;
Blumenthal, Roger ;
Danesh, John ;
Smith, George Davey ;
DeMets, David ;
Evans, Stephen ;
Law, Malcolm ;
MacMahon, Stephen ;
Martin, Seth ;
Neal, Bruce ;
Poulter, Neil ;
Preiss, David ;
Ridker, Paul ;
Roberts, Ian ;
Rodgers, Anthony ;
Sandercock, Peter ;
Schulz, Kenneth ;
Sever, Peter ;
Simes, John ;
Smeeth, Liam ;
Wald, Nicholas ;
Yusuf, Salim ;
Peto, Richard .
LANCET, 2016, 388 (10059) :2532-2561
[7]   DESIGNING A PRACTICE POLICY - STANDARDS, GUIDELINES, AND OPTIONS [J].
EDDY, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (22) :3077-&
[8]   COMPARING BENEFITS AND HARMS - THE BALANCE-SHEET [J].
EDDY, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (18) :2493-&
[9]   Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials [J].
Fulcher, Jordan ;
O'Connell, Rachel ;
Voysey, Merryn ;
Emberson, Jonathan ;
Blackwell, Lisa ;
Mihaylova, Borislava ;
Simes, John ;
Collins, Rory ;
Kirby, Adrienne ;
Colhoun, Helen ;
Braunwald, Eugene ;
La Rosa, John ;
Pedersen, T. R. ;
Tonkin, Andrew ;
Davis, Barry ;
Sleight, Peter ;
Franzosi, Maria Grazia ;
Baigent, Colin ;
Keech, Anthony ;
de Lemos, J. ;
Blazing, M. ;
Murphy, S. ;
Downs, J. R. ;
Gotto, A. ;
Clearfield, M. ;
Holdaas, H. ;
Gordon, D. ;
Koren, M. ;
Dahloef, B. ;
Poulter, N. ;
Sever, P. ;
Knopp, R. H. ;
Fellstroem, B. ;
Holdaas, H. ;
Jardine, A. ;
Schmieder, R. ;
Zannad, F. ;
Goldbourt, U. ;
Kaplinsky, E. ;
Colhoun, H. M. ;
Betteridge, D. J. ;
Durrington, P. N. ;
Hitman, G. A. ;
Fuller, J. ;
Neil, A. ;
Wanner, C. ;
Krane, V. ;
Sacks, F. ;
Moye, L. ;
Pfeffer, M. .
LANCET, 2015, 385 (9976) :1397-1405
[10]  
Kane S., 2020, ASCVD RISK CALCULATI